{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T15:16:53Z","timestamp":1771082213775,"version":"3.50.1"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"KEB: Allergan"}],"content-domain":{"domain":["jgaronline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.jgar.2017.07.015","type":"journal-article","created":{"date-parts":[[2017,7,31]],"date-time":"2017-07-31T14:32:13Z","timestamp":1501511533000},"page":"111-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Shifts in antimicrobial consumption and infection rates before and during a piperacillin\/tazobactam shortage"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0952-3321","authenticated-orcid":false,"given":"S. Travis","family":"King","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie E.","family":"Barber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason J.","family":"Parham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayla R.","family":"Stover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2017.07.015_bib0005","series-title":"Executive summary: a review of FDA\u2019s approach to medical product shortages","author":"US Food Drug Administration (FDA)","year":"2011"},{"key":"10.1016\/j.jgar.2017.07.015_bib0010","series-title":"Antibiotic resistance threats in the United States, 2013","author":"Centers for Disease Control and Prevention (CDC)","year":"2013"},{"key":"10.1016\/j.jgar.2017.07.015_bib0015","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1128\/AAC.05560-11","article-title":"Changes in the use of broad-spectrum antibiotics after cefepime shortage: a time series analysis","volume":"56","author":"Pl\u00fcss-Suard","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.07.015_bib0020","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1592\/phco.2006.26.1.61","article-title":"Impact of a piperacillin\u2013tazobactam shortage on antimicrobial prescribing and the rate of vancomycin-resistant enterococci and Clostridium difficile infections","volume":"26","author":"Mendez","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2017.07.015_bib0025","series-title":"Guidelines for ATC classification and DDD assignment 2013","author":"WHO Collaborating Centre for Drug Statistics Methodology","year":"2012"},{"key":"10.1016\/j.jgar.2017.07.015_bib0030","series-title":"55th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Change in meropenem utilization following the implementation of a targeted antimicrobial stewardship audit and feedback program","author":"Cretella","year":"2015"},{"key":"10.1016\/j.jgar.2017.07.015_bib0035","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/jac\/dkh127","article-title":"Increase in the rate of nosocomial Clostridium difficile-associated diarrhoea during shortages of piperacillin\u2013tazobactam and piperacillin","volume":"53","author":"Alston","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2017.07.015_bib0040","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ajic.2014.02.024","article-title":"Risk factors for the acquisition of carbapenem-resistant Escherichia coli at a tertiary care center in South Korea: a matched case\u2013control study","volume":"42","author":"Ahn","year":"2014","journal-title":"Am J Infect Control"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716517301431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716517301431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T17:29:33Z","timestamp":1535563773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716517301431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":8,"alternative-id":["S2213716517301431"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2017.07.015","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Shifts in antimicrobial consumption and infection rates before and during a piperacillin\/tazobactam shortage","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2017.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}